|
|
|
|
| LEADER |
04110nam a22005775i 4500 |
| 001 |
978-94-007-6467-5 |
| 003 |
DE-He213 |
| 005 |
20210617232257.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130507s2013 ne | s |||| 0|eng d |
| 020 |
|
|
|a 9789400764675
|9 978-94-007-6467-5
|
| 024 |
7 |
|
|a 10.1007/978-94-007-6467-5
|2 doi
|
| 050 |
|
4 |
|a R-RZ
|
| 072 |
|
7 |
|a MBGR
|2 bicssc
|
| 072 |
|
7 |
|a MED000000
|2 bisacsh
|
| 072 |
|
7 |
|a MBGR
|2 thema
|
| 082 |
0 |
4 |
|a 610
|2 23
|
| 245 |
1 |
0 |
|a Angiogenesis Modulations in Health and Disease
|h [electronic resource] :
|b Practical Applications of Pro- and Anti-angiogenesis Targets /
|c edited by Shaker A. Mousa, Paul J. Davis.
|
| 250 |
|
|
|a 1st ed. 2013.
|
| 264 |
|
1 |
|a Dordrecht :
|b Springer Netherlands :
|b Imprint: Springer,
|c 2013.
|
| 300 |
|
|
|a X, 206 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Preface -- Angiogenesis assays: an appraisal of current techniques -- Survey of pro-angiogenesis strategies -- Angiogenesis modulation by arachidonic acid – derived lipids: positive and negative regulators of angiogenesis -- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects -- Actions of steroids and peptide hormones on angiogenesis -- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.- Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment -- Impact of nanotechnology on therapeutic angiogenesis -- Survey of anti-angiogenesis strategies -- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis -- Integrin antagonists and angiogenesis -- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology -- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration -- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit -- Biomarkers of response and resistance to anti-angiogenic treatment -- Speculations on new directions in which angiogenesis may proceed. Index.
|
| 520 |
|
|
|a This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Neurosciences.
|
| 650 |
|
0 |
|a Pharmacy.
|
| 650 |
|
0 |
|a Life sciences.
|
| 650 |
|
0 |
|a Biotechnology.
|
| 650 |
|
0 |
|a Cell biology.
|
| 650 |
1 |
4 |
|a Biomedicine, general.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B0000X
|
| 650 |
2 |
4 |
|a Neurosciences.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B18006
|
| 650 |
2 |
4 |
|a Pharmacy.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/F00008
|
| 650 |
2 |
4 |
|a Life Sciences, general.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/L00004
|
| 650 |
2 |
4 |
|a Biotechnology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/C12002
|
| 650 |
2 |
4 |
|a Cell Biology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/L16008
|
| 700 |
1 |
|
|a Mousa, Shaker A.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 700 |
1 |
|
|a Davis, Paul J.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789400764682
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789401785150
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789400764668
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-94-007-6467-5
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 912 |
|
|
|a ZDB-2-SXB
|
| 950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
| 950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|
